Personalis, Inc. shared a post on X:
“Major news: Medicare now covers NeXT Personal® MRD testing for LungCancer surveillance!
- Coverage applies for surveillance of stage I-III NSCLC patients.
- Coverage determination backed by groundbreaking TRACERx data (published in Cell).
- NeXT Personal detects residual disease with high accuracy.
With 230K new lung cancer cases annually and the risk of recurrence a top concern, this coverage gives patients and doctors a powerful tool to navigate uncertainty in their cancer journey.”
Other articles on OncoDaily.